George Sands, Nisha Bansal and Wolfgang C. Winkelmayer/LinkedIn
Jun 5, 2026, 18:32
George Sands: A Thoughtful Editorial on Low-Dose Rivaroxaban in Advanced CKD
George Sands, Ex-Senior Medical Director of Pfizer, Principal of Sands Collaborative, shared a post on LinkedIn about a recent article by Nisha Bansal and Wolfgang C. Winkelmayer, published in JAMA, adding:
“Sharing a very thoughtful editorial by Bansal and Winkelmyer about a trial in CKD patients, stage 4 and 5.
This randomized study is very helpful. This patient population is very challenging to randomize in clinical trials.
This was a placebo-controlled trial vs low-dose rivaroxaban.
The editorial sums it all up beautifully; approximately 5-minute read.”
Title: Rivaroxaban for Cardiovascular Disease Prevention in Chronic Kidney Disease
Authors: Nisha Bansal, Wolfgang C. Winkelmayer
Stay updated on all sceintific advances with Hemostasis Today.
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!
-
Jul 13, 2026, 05:57Barbara Adams Krolak: Exciting Updates From the ISTH 2026 Regulatory Session